Panel of Unique Myeloma Cell Lines
Diag2tec has a unique large collection of Human Myeloma Cell Lines (HMCLs, n=40) including 25 cell lines derived from MM patients from Montpellier hospital and dependent on exogenous IL-6 for growing and survival. The latter stop cell cycling and enter apoptosis after removal of exogenous cytokines and constitute a relevant model to study the function of drugs and underlying drug resistance mechanisms. We previously demonstrated that cell lines are representative of the molecular heterogeneity described in patients with 6 different molecular subgroups (publication and patent here).
We have characterized our MM cell lines collection using RNA seq, Exome Seq, CHIP seq (6 histone marks), DNA methylation, SNP and Affymetrix GEP. In addition, immunophenotypic and cytogenetic characterization of all HMCLs has been carried out. Moreover, we have also characterized the HMCLs response to 20 molecules/drugs (melphalan, lenalidomide, pomalidomide, bortezomib, carfilzomib, cell cycle inhibitor, kinases inhibitors, HDACi, DNMTi, EZH2 inhibitor, DNA repair inhibitors…), (see publications and patents here).
We have also derived human myeloma cell lines resistant to Proteasome inhibitors, IMiDs, Dexamethasone, Melphalan and, HDACi (publication in revision).
With these fully characterized cell lines, Diag2Tec offers you the possibility to screen our anti-myeloma drugs, to investigate the drug resistance and associated mechanisms of action of your specific molecule.
In a recent study, we present for the first time the mutational landscape of human myeloma cell lines. We conducted whole-exome sequencing (WES) on 30 HMCLs and we identified mutations in genes involved in key pathways in MM and mutations known as associated with drug resistance. This publication confirms the interest of our cell lines to study the mechanism of resistance of therapeutic agent in MM and to identify new biomarkers to predict the response of cancer cells. (publication here)
B and T Lymphoma Cell Lines
Diag2tec provides services on our various collection of B-cell and T-cell lymphoma cell lines with approximately:
- 16 human Diffuse Large B Cell Lymphoma (DLBCL) cell lines
- 7 human Mantle Cell Lymphoma (MCL) cell lines
- 8 human T-cell Lymphoma (CTCL, ALCL, NK-TLL).
We have characterized the majority of these cell lines to the response of conventionnal drugs. This is interesting to assess combo treatments or to select sensitive/resistant cell lines for cytoxicity assays.
We also have access to the gene expression profiles and their mutational status for the majority of these cell lines.
Leukemia Cell Lines
Diag2tec also has access to 15 Acute Myeloid Leukemia cell lines (AML) from different FAB subgroups.
We have the gene expression profiles and the mutational status of these cell lines to assess your targets gene expression and mutations of interest.
Using our cellular models, we provide you a large range of services to investigate the effect of your molecules alone or in combination treatment.
